title: Transforming growth factor-beta1 suppresses atopic dermatitis-like skin lesions in NC/Nga mice.
abstract: BACKGROUND
  Atopic dermatitis is a chronic, relapsing inflammatory disorder characterized by pruritic and eczematous skin lesions. Transforming growth factor (TGF)-beta1 has been implicated in the suppression of inflammatory responses.
  
  
  OBJECTIVE
  The purpose of this study is to determine whether TGF-beta1 suppresses skin lesions in a mouse model of atopic dermatitis.
  
  
  METHODS
  We used the NC/Nga strain of mice as an in vivo model of atopic dermatitis. The effects of exogenous TGF-beta1 on atopic dermatitis-like skin lesions in NC/Nga mice were evaluated clinically, histologically and immunologically.
  
  
  RESULTS
  Subcutaneous injection of recombinant TGF-beta1 macroscopically suppressed eczematous skin lesions in NC/Nga mice associated with reduced serum immunoglobulin E (IgE) levels. Histological analysis showed that TGF-beta1 significantly inhibited the infiltration of inflammatory cells such as mast cells and eosinophils into the skin of NC/Nga mice. Spontaneous interferon (IFN)-gamma production from splenocytes of NC/Nga mice was down-regulated by the treatment with TGF-beta1 and neutralizing antibody against IFN-gamma inhibited skin lesions in NC/Nga mice. The inhibitory effect of TGF-beta1 on the skin lesions lasted at least 1 week after cessation of the treatment.
  
  
  CONCLUSIONS
  These findings indicate that TGF-beta1 suppressed atopic dermatitis-like skin lesions in NC/Nga mice at least in part through down-regulation of IFN-gamma. These results suggest that TGF-beta1 may have a therapeutic potential for atopic dermatitis.
authors.affiliation: Atopy (Allergy) Research Center Department of Dermatology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Sumiyoshi
authors.forename: A
authors.initials: A
authors.lastname: Nakao
authors.forename: H
authors.initials: H
authors.lastname: Ushio
authors.forename: K
authors.initials: K
authors.lastname: Mitsuishi
authors.forename: K
authors.initials: K
authors.lastname: Okumura
authors.forename: R
authors.initials: R
authors.lastname: Tsuboi
authors.forename: C
authors.initials: C
authors.lastname: Ra
authors.forename: H
authors.initials: H
authors.lastname: Ogawa
mesh_terms: D000818:Animals; D000906:Antibodies / Q000494:pharmacology; D003876:Dermatitis, Atopic / Q000378:metabolism / Q000473:pathology*; D004195:Disease Models, Animal; D007073:Immunoglobulin E / Q000032:analysis; D007371:Interferon-gamma / Q000037:antagonists & inhibitors / Q000276:immunology / Q000378:metabolism; D051379:Mice; D008815:Mice, Inbred Strains; D011994:Recombinant Proteins / Q000494:pharmacology; D013154:Spleen / Q000378:metabolism / Q000473:pathology; D016212:Transforming Growth Factor beta / Q000494:pharmacology*; D053773:Transforming Growth Factor beta1
chemical_list: D000906:Antibodies; D011994:Recombinant Proteins; C508961:Tgfb1 protein, mouse; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; D007073:Immunoglobulin E; D007371:Interferon-gamma